Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

24 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Zydus Cadila Articles

Mylan debuts generic Antara; FDA approves generics of Actavis' Suboxone, Lupin's Suprax and Zydus' Zantac

25 February 2013

Zydus Cadila unit launches udenafil for erectile dysfunction in India

18 July 2012

Zydus Cadila third-quarter revenues up 20%

7 February 2012

Zydus Cadila acquires Mumbai-based Biochem

21 December 2011

Ranbaxy debuts generic Femara in UK, France and Romania; FDA OKs Zydus plant

26 July 2011

Zydus Cadila 1st-qtr fiscal net profit jumps 15%

20 July 2011

K-V Pharma sells generics unit to Zydus for $60 million

20 June 2011

Zydus Cadila joins Indian billion dollar league

5 April 2011

Karo Bio and Zydus Cadila extend anti-inflammatory research agreement

23 March 2011

Bayer sets up marketing JV deal with India’s Zydus Cadila to strengthen pharma business in India

31 January 2011

Nycomed progresses its BRIC ambitions, soon to announce Chinese acquisition and opening Indian APIs plant in JV with Zydus

4 October 2010

Shire files suit against Cadila/Zydus Cadila for Lialda patent infringement

9 July 2010

Zydus tells Shire it has filed US ANDA for ulcerative colitis drug Lialda

1 June 2010

Abbott Labs targets emerging markets via Zydus Cadila collaboration; creates stand-alone generics unit

12 May 2010

Showing 1-14 of 14 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Is the diabetes market facing a blockbuster-free future?
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Is the diabetes market facing a blockbuster-free future?
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS